Larazotide vs Thymosin β-4.

Larazotide (larazotide acetate, research code AT-1001) is a synthetic eight-amino-acid peptide investigated as an oral, gut-restricted therapy for celiac disease. It was designed to act locally in the small intestine rather than being absorbed systemically. The concept was to add a first non-dietary treatment for patients who still have symptoms despite a gluten-free diet. It advanced through Phase 2 and into Phase 3 development but is not approved by the FDA or any major regulator. It is categorized under healing because its target is intestinal barrier repair and integrity.

Thymosin beta-4 (Tβ4) is a small, naturally occurring 43-amino-acid acidic peptide found in nearly all mammalian cells and in high concentrations in platelets, wound fluid, and many tissues. It is the principal member of the beta-thymosin family and is one of the most abundant actin-binding proteins in the cytoplasm. The injectable "research peptide" TB-500 is widely marketed as thymosin beta-4, but it is typically a synthetic fragment or analog of the parent molecule rather than the full-length, naturally sequenced peptide; the two are not strictly interchangeable.

Larazotide is a tight-junction regulator, often described as a zonulin antagonist. In celiac disease, gluten exposure is associated with increased release of zonulin and loosening of the tight junctions between intestinal epithelial cells, allowing gluten peptides to cross the barrier and drive immune activation. Larazotide is proposed to promote tight-junction assembly and reduce paracellular permeability (leaky gut), thereby limiting gluten peptide entry and downstream inflammation. It is intended to work in the gut lumen, which fits its minimal systemic absorption. The precise molecular target and the physiological role of zonulin itself remain areas of scientific debate.

Tβ4's best-characterized molecular function is sequestering monomeric (G-)actin: it binds G-actin in a roughly 1:1 ratio, buffers the pool of unpolymerized actin, and thereby regulates cytoskeletal assembly, cell migration, and motility. Beyond this structural role, Tβ4 has been reported to upregulate cell-survival signaling, notably activation of integrin-linked kinase (ILK) and the Akt pathway in cardiac cells, and to influence angiogenesis, inflammation, and the actin-binding protein laminin/myosin machinery during tissue remodeling. It also has downstream effects attributed to its N-terminal tetrapeptide (Ac-SDKP), a cleavage product with antifibrotic and anti-inflammatory activity. These mechanisms are largely defined in cell-culture and animal systems.

Mid-stage data were encouraging but the definitive trial did not succeed. In a Phase 2b randomized, double-blind, placebo-controlled trial (Leffler et al., Gastroenterology, 2015; 342 patients with persistent symptoms despite a gluten-free diet), low-dose larazotide reduced patient-reported symptoms versus placebo, with the lowest dose showing the clearest signal. On the strength of such results the program advanced to a large Phase 3 trial (CeD-2001) run by 9 Meters Biopharma. That Phase 3 study was halted after an interim analysis indicated it was unlikely to meet its primary endpoint, the change from baseline in celiac symptom severity, effectively ending the program. In short: positive Phase 2b data did not translate into a successful Phase 3 result, and larazotide is not an approved therapy. Several features of the earlier evidence look different in hindsight. The Phase 2b result was strongest at the lowest dose tested, without a conventional dose-response relationship, a pattern that is difficult to interpret mechanistically and that often does not reproduce. Primary endpoints across the program were patient-reported symptom scores rather than histology or objective mucosal healing, and symptom scores in celiac disease are noisy and prone to large placebo responses. Supporting biology exists outside these trials: larazotide acetate promoted recovery of ischemia-injured porcine jejunum through repair of tight junctions (PLoS One, 2021), and reviews of celiac pharmacotherapy place tight-junction regulation among several strategies that have been tried without yet producing an approved drug (European Journal of Pharmacology, 2021). The comparison that matters is with existing management. A strict lifelong gluten-free diet remains the only established treatment for celiac disease, supported by decades of clinical experience and by histologic and serologic recovery in patients who adhere to it. No drug has been approved as an adjunct or replacement. Larazotide reached the last stage of testing and failed there, so the honest summary is that the leading non-dietary candidate did not demonstrate benefit when tested at confirmatory scale.

The strongest human clinical data come from ophthalmology: the full-length peptide as RGN-259 (0.1% Tβ4 ophthalmic solution, RegeneRx/regional partners) was studied in a randomized, placebo-controlled, double-masked Phase III trial in neurotrophic keratopathy (Int J Mol Sci 2022, PMID 36613994), and in the ARISE-1/-2/-3 Phase III dry-eye program, where ARISE-3 missed its co-primary endpoints but showed significant improvement in some pre-specified secondary sign/symptom measures with a clean safety profile. Most other applications remain preclinical: the landmark cardiac work (Bock-Marquette et al., Nature 2004, PMID 15565145) showed Tβ4 promoted cardiomyocyte migration, survival, and improved cardiac function after injury in mice via ILK/Akt, and dermal/corneal wound-healing benefits are documented in animal models (e.g., Sosne et al., Exp Eye Res 2002, PMID 11950239). There is no FDA-approved Tβ4 product and no robust human evidence for the systemic "tissue repair," tendon/muscle recovery, or anti-aging uses for which TB-500 is informally promoted; that gap between animal data and proven human benefit is substantial.

Across trials larazotide was generally well tolerated, consistent with a peptide that acts locally in the gut and is minimally absorbed. Reported adverse events were typically mild and gastrointestinal, such as abdominal discomfort, nausea, or headache, and were often similar between drug and placebo groups. Minimal systemic absorption limits the plausibility of effects outside the intestinal lumen, and no distinctive organ toxicity emerged as a program-stopping signal; the Phase 3 trial was discontinued for likely futility on efficacy, not for safety. Because development stopped before approval, there is no long-term real-world safety dataset in a broad treated population. Clinical trial exposure was limited in duration and confined to selected participants who met entry criteria, so effects of use over years, in children, in pregnancy, in older patients with comorbidities, or alongside common medications were never characterized. There is no post-marketing pharmacovigilance stream because there is no marketed product, and no regulator has reviewed a complete safety dossier. Anything sold as larazotide outside a clinical trial carries the separate risks of unapproved supply: no verified identity or purity, no batch testing, no good manufacturing practice oversight, and no adverse-event reporting. There is also an indirect risk specific to celiac disease, since any product presented as protection against gluten exposure could encourage relaxation of the gluten-free diet, which remains the only established management and the only intervention shown to allow mucosal recovery. This entry is educational only and is not a recommendation to obtain or use the compound, which is not an approved medicine.

In the controlled ophthalmic trials, topical Tβ4 (RGN-259) was generally well tolerated with a safety profile comparable to placebo, but those data are limited to eye-drop administration and do not establish the safety of systemic injection. For injectable TB-500 sold as a research chemical, there are essentially no published controlled human safety data: long-term effects, immunogenicity, and risks are not characterized in humans. A specific theoretical concern is Tβ4's role in cell migration and angiogenesis, which has prompted caution about effects on tumor growth or metastasis; some preclinical studies link elevated Tβ4 to more aggressive tumor behavior. Material sold outside regulated channels also carries contamination, mislabeling, and dosing-uncertainty risks. No doses or protocols are provided here.

Larazotide is investigational and is not approved by the FDA or EMA for celiac disease or any other indication. It reached Phase 3, but the pivotal CeD-2001 trial was discontinued for likely futility on its primary endpoint. Any product sold as larazotide outside of a clinical trial is not an approved drug.

Thymosin beta-4 is not FDA-approved for any indication; the full-length peptide (RGN-259) is investigational, completed Phase III trials in eye disease, and has held orphan-drug designation but no marketing approval, while injectable TB-500 is sold only as a research-use/unapproved compound. It is prohibited in sport at all times by WADA under section S2 (peptide hormones, growth factors, related substances and mimetics).